This is the report of an exploratory analysis from the phase 2 CELESTIAL trial of cabozantinib vs placebo in previously treated advanced HCC, which evaluated outcomes according to plasma biomarker levels. Plasma biomarkers were evaluated at baseline and during treatment. Hazard ratios for OS and PFS favored cabozantinib over placebo at low and high baseline levels for all biomarkers. No baseline biomarkers were predictive of a treatment benefit. Cabozantinib promoted pharmacodynamic changes in several biomarkers but these changes were not associated with OS or PFS. Low baseline levels of MET, HGF, GAS6, IL-8, and ANG2 and high levels of IGF-1 were identified as potential favorable prognostic biomarkers for survival.

(Rimassa, L., et al. – Liver Cancer, December 2021)

Read more